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Abstract
Pancreatic ductal adenocarcinoma, which accounts for the majority of pancreatic cancers,
is a lethal disease with few therapeutic options. Genomic profiling of pancreatic ductal
adenocarcinoma has identified a complex and heterogeneous landscape. Understanding
the molecular characteristics of pancreatic ductal adenocarcinoma will facilitate the identi-
fication of potential therapeutic strategies. We analyzed the gene expression profiles of
primary tumors from patients compared to normal pancreas and identified high co-overex-
pression of core components of the spindle assembly checkpoint, including the protein
kinase TTK (also known as MPS-1). We found overexpression of TTK protein in a subset
of pancreatic ductal adenocarcinoma primary tumors and cell lines. siRNA-mediated
depletion or catalytic inhibition of TTK resulted in an aberrant cell cycle profile, multi- and
micro-nucleation, induction of apoptosis, and decreased cell proliferation and transformed
growth. Selective catalytic inhibition of TTK caused override of the spindle assembly
checkpoint-induced cell cycle arrest. Interestingly, we identified ubiquitin specific pepti-
dase 16 (Usp16), an ubiquitin hydrolase, as a phosphorylation substrate of TTK. Usp16
regulates chromosomal condensation and G2/M progression by deubiquitinating histone
H2A and polo-like kinase 1. Phosphomimetic mutants of Usp16 show enhanced proteoso-
mal degradation and may prolong the G2/M transition allowing for correction of replication
errors. Taken together, our results suggest a critical role for TTK in preventing aneuploidy-
induced cell death in pancreatic cancer.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) represents 85% of all pancreatic cancers [1] and is
projected to be the third leading cause of cancer related deaths in the United States in 2016 [2].
Median survival of pancreatic cancer patients is five to eight months with fewer than 5% of
patients surviving longer than five years after diagnosis. The poor prognosis stems from the
frequent presence of metastatic disease at the time of or shortly after diagnosis. The current
standard of care for metastatic pancreatic cancer is chemotherapy. Although chemotherapeu-
tic approaches including gemcitabine, nab-paclitaxel, and FOLFIRINOX have improved
patient survival [3–5], the discovery of new and better drug targets remains essential for the
continued improvement of therapies for PDAC.
Genomic and mouse model studies have advanced our understanding of PDAC tumor
biology and have identified a high degree of chromosomal instability in PDAC [6–8]. One
aspect of chromosomal instability is the unequal segregation of chromosomes during mito-
sis, resulting in aberrant chromosomal numbers and cellular aneuploidy of both daughter
cells [9]. It has long been postulated that chromosomal instability is an important mecha-
nism for tumor adaptation [10,11]. However, recent studies have hypothesized that the adap-
tive capacity of cancer cells to aneuploidy is limited [12,13]. Aneuploid cancer cells must
maintain a delicate balance between sustaining an altered genome that enhances prolifera-
tion yet confines continued chromosomal instability within survivable limits [14,15]. As
such, there is a pressing need to characterize the adaptive mechanisms that control this bal-
ance to potentially identify therapeutic targets that can shift this balance from sustainable to
non-viable chromosomal instability.
Chromosomal segregation during mitosis is a multi-step process and errors during segrega-
tion often result in aneuploidy [16]. Therefore, the timing of each step is tightly regulated to
maintain high levels mitotic fidelity. In normal cells, mitotic checkpoints ensure that each step
is completed prior to continuing through the next phase of the cell cycle. The importance of
these checkpoints in cancer is an area of current interest as inactivation of mitotic checkpoints
has been shown to enhance chromosomal instability [17], which may result in aneuploidy and
decreased cellular fitness.
The spindle assembly checkpoint (SAC) is a conserved mitotic checkpoint found from
yeast to mammals that ensures accurate segregation of chromosomes during mitosis. During
metaphase, sister chromatids congregate at the metaphase plate prior to separation during
anaphase. The SAC is activated to prevent the premature onset of anaphase until bi-oriented
microtubule attachment occurs at each kinetochore. Failure to activate the SAC has previously
have been shown to promote chromosomal instability [9,14,15,18].
SAC activation requires the expression and activity of the protein kinase TTK, also known
as Mps1/Pyt/CT96 [19]. Overexpression of TTK has been proposed to be an adaptive mecha-
nism whereby cells cope with aneuploidy. In agreement with this hypothesis, high levels of
TTKmRNA have been observed in multiple cancer types and been shown to be protective
against aneuploidy [20–26]. Previous studies have investigated the role of TTK in cancer using
pharmacologic inhibitors in cancer cell lines. Pharmacologic inhibition of TTK in colorectal
and glioblastoma cancer cell lines reduced cell viability, caused aberrant cell cycle progression,
increased aneuploidy, and increased apoptosis [27–31]. Similarly, two recent studies provide a
tantalizing rationale to elucidate the role of TTK overexpression in PDAC. Slee et al. found
that pharmacologic inhibition of TTK in PDAC caused aberrant override of SAC-dependent
cell cycle arrest, increased chromosomal instability, increased apoptosis and decreased clono-
genic survival [32]. Kaistha et al. found that genetic depletion of TTK increased apoptosis and
decreased PDAC cell line proliferation and was associated with high levels of chromosomal
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instability [33]. These studies clearly demonstrate the importance for TTK in continued
PDAC growth, yet several questions remain unanswered about the biological role of TTK in
PDAC. First, the efficacy of alternative TTK selective inhibitors with differing specificity pro-
files has not been characterized. Second, the consequences of acute suppression of TTK func-
tion on PDAC growth remain undetermined. Third, the phosphorylation substrates required
for TTK-dependent growth remain poorly characterized. Finally, the requirement of TTK for
cellular transformation and in vivo tumorigenesis in PDAC has not been evaluated. In addi-
tion, these and other studies clearly implicate the importance of TTK catalytic activity for con-
tinued PDAC cell line growth, yet how TTK promotes growth remains unclear. The list of
identified TTK phosphorylation substrates remain sparse and the key substrates for TTK-
dependent cancer growth remain unestablished [34–37].
The overall goal of this study was to investigate the role of TTK in mitotic progression, pro-
liferation and transformation of PDAC and identify the molecular mechanism whereby TTK
limits chromosomal instability. We found increased mRNA expression of core SAC compo-
nents and elevated mRNA and protein expression of TTK in a subset of PDAC cell lines and
human tumors, suggesting that TTK might protect cells from excessive chromosomal instabil-
ity through SAC activation. We also found that TTK phosphorylates and regulates the protein
stability of Usp16, an enzyme required to promote chromosomal condensation, suggesting
that TTK functions at multiple stages of the cell cycle to maintain genome stability. Together
these findings help explain the role of TTK in adapting to and maintaining viable levels of
aneuploidy in PDAC.
Materials and methods
Tissue collection
After approval from the University of North Carolina at Chapel Hill Institutional Review
Board, de-identified tissue samples were obtained from the UNC Tissue Procurement Core
Facility. Consent was not obtained because no identifiers were available to the investigators and
the data was analyzed anonymously. Flash-frozen human tumor tissue samples were homoge-
nized in NP-40 lysis buffer, resolved by SDS—PAGE, and evaluated by western blot analysis.
RNA microarray analysis
Gene expression microarray data of 132 normal and primary pancreatic tumor samples from
patients were obtained from the Gene Expression Omnibus (GEO) database (accession num-
ber GSE21501). Normalization, quality control, and imputation of array data were performed
as previously described [38]. Expression data from multiple probes were collapsed by the
mean for each sample. Statistical significance was assessed using a two-tailed unpaired t-test
comparing SAC component expression in normal versus tumor tissue. Differentially expressed
genes were identified using statistical analysis of microarrays (SAM) and a 5% false discovery
rate (FDR) [39]. Gene networks were investigated for enrichment of differentially expressed
kinases using Ingenuity Pathway Analysis (IPA, Ingenuity Systems).
Cell culture and reagents
All cell lines except HPDE, HPNE, 293FT, HuPT3 were obtained from American Type Culture
Collection (ATCC, LGC Promochem). The HPV16-E6-E7 immortalized human HPDE cell
line was obtained from Ming-Sound Tsao (University of Toronto, Toronto) [40]. The HuPT3
cell line was obtained from Dan Billadeau (Mayo Clinic, Rochester, MN). 293FT cells were
purchased from Invitrogen. The HPV16-E6E7-immortalized human HPNE cell line was
TTK inhibition impairs pancreatic cancer growth
PLOS ONE | https://doi.org/10.1371/journal.pone.0174863 April 5, 2017 3 / 22
obtained from Michel Ouellete (UNMC Eppley Cancer Center) and has been described previ-
ously [41,42]. All cell lines were maintained at 37˚C and 5% CO2. HPAC, PANC-1, MIA
PaCa-2, T3M4, HPAF-II, HPNE, HPDE, 293T, 293FT, and HeLa cell lines were cultured in
Dulbecco’s Modified Eagle Medium (DMEM, Corning). BxPC-3, Panc 02.03, Panc 10.05,
AsPC-1, SW-1990, HuPT3, CFPAC-1, Capan-1 and Capan-2 cell lines were maintained in
RPMI-1640 with 4.5 g/L glucose. All growth media were supplemented with 10% (vol/vol)
fetal bovine serum (FBS, Hyclone), and 100 U/ml penicillin and 100 U/ml streptomycin (P/S,
Gibco). Capan-1 cells which were supplemented with 15% (vol/vol) FBS.
Antibodies
Primary antibodies used for immunoblot or immunoprecipitation include: Mouse anti-β-actin
(IB, 1:5000, AC-15, Sigma Aldrich), mouse anti-TTK (IB, 1:2000, 4-112-3 Millipore), rabbit
anti-Cyclin B1 (IB, 1:1000, 4138 Cell Signaling), rabbit anti-Histone H3 phospho Ser 10 (IB,
1:1000, 9701 Cell Signaling), mouse anti-FLAG (IB, 1:1000, M2 Sigma Aldrich), mouse anti-
phospho tyrosine (IB, 1:1000, 9411 Cell Signaling), mouse anti-phospho serine (IB, 1:1000,
4A4 Millipore), mouse anti-phospho threonine (IB, 1:1000, Cell Signaling 3986) rabbit anti-
Usp16 (IB, 1:2000, Bethyl A301-615A), mouse anti-HA (1:1000, Covance 16B12), and mouse
anti-green fluorescent protein (GFP) (1:5000 Clontech JL8). HRP conjugated secondary anti-
bodies included goat anti-mouse (1:10,000, Thermo) or goat anti-rabbit (1:10,000, Thermo).
Immunoprecipitation and immunoblotting
Two to five μg of specified antibodies were bound to 20–50 μl of Protein G Dynabeads (Invi-
trogen) overnight at 4˚C. Cells were collected following treatments as specified in the figure
legends. Cells were harvested and then lysed in NP-40 lysis buffer (50 mM Tris pH 7.5, 10 mM
MgCl2, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, and 10% glycerol) supple-
mented with phosphatase (Roche) and protease (Sigma) inhibitor cocktails. Cell lysates were
incubated with antibody bound Dynabeads overnight at 4˚C. Beads were washed three times
with lysis buffer and resuspended in protein sample buffer containing β-mercaptoethanol and
examined by immunoblotting.
Immunoblots were performed by running protein samples on either 15% (for proteins
under 40 kDa) or 8% SDS-PAGE followed by transfer of resolved proteins to PVDF mem-
branes for 90 min at 4˚C. All immunoblots were blocked in 5% milk/TBST solution for 1 h at
room temp with gentle agitation. Primary antibodies were diluted in 5% (weight/vol) milk or
5% BSA. Primary antibodies were incubated overnight at 4˚C. Following incubation with pri-
mary antibody, blots were washed with TBST and then incubated with secondary HRP-conju-
gated antibodies for 1 h at room temp with gentle agitation. Blots were again washed with
TBST and developed by ECL/chemiluminescence and autoradiograph film (Kodak) or the
Biorad XRS+ imaging system.
FLAG pull-downs were performed on cell lysates using the pull-down buffer (50 mM Tris
pH 7.6, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM EGTA)
and supplemented with protease inhibitors (Roche). Lysates were clarified by centrifugation.
Ten mg of protein were used in each pull down. Anti-FLAG M2 magnetic beads (Sigma) were
used to immunoprecipitate FLAG-tagged Usp16. Following extensive washing with TBS, FLA-
G-Usp16 was eluted with FLAG peptide (Sigma) in TBS.
cDNA expression
The pLenti CMV Puro LUC (w168-1) expression vectors for firefly luciferase was a gift from
Eric Campeau (Addgene plasmid #17477) [43], Flag-HA-USP16 was a gift from Wade Harper
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(Addgene plasmid # 22595) [44]. GFP-Usp16 was prepared by amplifying Usp16 cDNA from
FLAG-HA-Usp16 followed by subcloning into pEGFP-C3 using the XhoI and BamHI sites.
GFP-Usp16 3xA and 3xE were prepared by site-directed mutagenesis and confirmed by
sequencing.
Transfections for all cDNA were accomplished using an HBS/CaCl2 or TransIT-LT1 (Mir-
ius Bio) protocol and cells were examined for expression 48–72 h post transfection
shRNA constructs and infection
pLKO.1 shRNA lentiviral plasmids were obtained from the UNC lentiviral RNAi core facility
including: shTTK_3 (TRCN0000006358) and shTTK_4 (TRCN0000011011).
To establish stably infected pancreatic cells expressing shRNA, pLKO.1 lentiviral vector
was transiently transfected into 293T cells with the pCMV-VSV-G (Addgene plasmid #8454),
pMDLg/pRRE (Addgene plasmid #12251) and pRSV-Rev (Addgene plasmid #12253) packag-
ing plasmids using HBS/CaCl2 transfection reagent. Viral supernatants were collected and
infection of PDAC cell lines was performed in growth media supplemented with 8g/ml poly-
brene. Cells stably expressing the shRNA were selected by culturing the cells in media contain-
ing 1.0–2.0 μg/ml puromycin. Following selection, cells were maintained in puromycin at one-
half the concentration used for selection.
siRNA transfection
All siRNA described were obtained from Thermo and are part of the ON-TARGETplus
SMARTpools of siRNA. siRNAs were transfected using RNAiMax (Invitrogen).
Cell proliferation assays
For the MTT viability assay, 3 x 105 cells were transfected with siRNA using RNAiMax trans-
fection reagent. Forty-eight h post transfection 1 x 103 cells were plated into 6 identical wells of
a 96-well plate. Proliferation was assessed by addition of the MTT reagent for 4 h. Measure-
ments were taken at A560 on the Synergy 2 (Biotek Instruments).
For the soft agar colony formation assay, 104 siRNA-transfected cells were suspended
between layers of 0.6% (bottom) and 0.3% (top) bacto-agar (BD Biosciences) in three wells of a
6-well dish. Cells were supplied with growth medium twice a week and allowed to form colo-
nies for 7–28 days. Colonies were visualized by staining with MTT (2 mg/ml). Colonies were
imaged and quantitated using ImageJ (National Institute of Health).
Cell cycle analysis by flow cytometry
DNA content was assayed using propidium iodide. Cells were harvested, washed and fixed in
70% ethanol. Cells were permeabolized with 0.5% Triton X-100 and stained with propidium
iodide. Stained cells were quantitated on the CyAN flow cytometer (Beckman Coulter). Distri-
bution of cells in each stage of the cell cycle was performed using ModFit (Verity Software
House).
Immunofluorescence
PANC-1 and HPAC cells were plated on poly-L-lysine (Sigma) coated coverslips. Cells were
fixed in 4% paraformaldehyde, permeabolized with 0.2% Triton X-100. Cells were then
blocked in 5% BSA in PBS. Cells were allowed to stain for 2 h at room temperature, washed
three times with PBS. Alexa Fluor-conjugated secondary antibodies (Invitrogen) and DAPI
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were allowed to bind for 1 h. Stained cells were washed three times with PBS, followed by one
wash with distilled water. Coverslips were then mounted with Fluorsave (Calbiochem).
All confocal images were obtained on a Zeiss 710 spectral confocal laser scanning confocal
microscope equipped with a 405, 458, 488, 514, 543, 594, 633 nm excitation lines. Images were
obtained using a 40X or 63X oil plan/Apo objective. Multicolor images were acquired using
sequential scanning. All images were visualized using ImageJ and cropped using Adobe Photo-
shop version CS3.
Apoptosis evaluation
Apoptosis was evaluated using an Annexin V assay (Roche) following the manufacturer’s pro-
tocol. Live cells were harvested in Tryp-LE (Gibco), washed in PBS, incubated in binding
buffer with FITC conjugated Annexin V. Necrotic cells were discriminated by using a propi-
dium iodide counterstain. Stained cells were quantitated on the CyAN flow cytometer (Beck-
man Coulter). At least 10,000 events were analyzed for each sample.
The Caspase-Glo 3/7 Assay kit (Promega, Madison, WI) was used to measure apoptotic
behavior in cells following the manufacturer’s protocol. Briefly, cells were transfected with
siRNA and 100 μL was transferred to a 96-well tissue culture plate with black walls and clear
bottom. Cells were incubated for 72 h. For drug treated cells, cells were given 24 h to adhere to
the plate prior to treatment. Cells were then treated with 2 μM AZ3146 (72 h), 0.1% DMSO
(24 h), or 2 μM staurosporine (24 h) in 100 μL of media. Luminescence substrate for caspase
3/7 (100 μL) was added to each well and gently mixed. The samples were incubated for 90 min
in the dark at room temperature and luminescence was measured in a Synergy 2 plate reader
(BioTek Instruments) as directed by the manufacturer. Each treatment group is represented in
triplicate.
P32 incorporation assay
Kinase assays were performed using recombinant active GST-tagged TTK (SignalChem). FLA-
G-Usp16 was purified from 293FT cells stably expressing FLAG-Usp16. Kinase assay was per-
formed at 30˚C for 15 and 30 min in 50 μl assay buffer (5 mM MOPS pH 7.2, 2.5 mM beta
glycerol phosphate, 5 mM MgCl2, 1 mM EGTA, 0.4 mM EDTA, 200 μM ATP, 0.4 mCi/ml
[U-32P]ATP, 50 μM DTT, 50 ng/μl BSA). Five microliters of the reaction was spotted onto
Whatman P81 cellulose phosphate filter paper. The filter paper was washed with 10% phos-
phoric acid three times for 5–10 min each to quench the reactions. Filter paper was washed
once with ethanol and dried. Filter papers were placed into scintillation vials, scintillation fluid
was added to each vial, and 32P incorporation was assessed on the Beckman LS6500 (Beckman
Coulter).
Phosphopeptides enrichment and mass spectrometry
Following trypsin digestion with FASP protocol using spin filter column (Sartorius Vivacon
500 30kD cutoff), the peptides mixture was reduced to about 100 μl by vacuum centrifugation.
Titanium dioxide tips (GL Sciences Phos-TiO Kit, 1404024) was used to enrich phosphopep-
tides afterwards. In brief, the peptides mixture was loaded to the TiO2 tip first. After equilibra-
tion and washing, phosphopeptides were eluted off the tips with 50 μl 5% ammonium
hydroxide solution (Fisher Chemical Optima grade, A470-250) and 50 μl 5% pyrrolidine solu-
tion (Acros Organics, AC44614-1000). The eluate was concentrated to a volume of 5 μl or less
in SpeedVac concentrator, and reconstituted with 0.1% FA water for mass spectrometric anal-
ysis (Thermo Orbitrap Elite mass spectrometer).
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Results
High expression of spindle assembly checkpoint kinases identified in
PDAC
Mutations in protein kinases underlie many human diseases, including cancer, and previous
success of FDA approved kinase inhibitors make protein kinases an attractive class of highly
druggable molecular targets [45]. However, the percent of the kinome with at least one varia-
tions that affects protein coding (missense/deletion/frame shift) is lower in PDAC (75%) com-
pared to breast (94%), lung (86%), and colon (93%) cancers [46–49] (https://tcga-data.nci.nih.
gov/). Gene amplifications and overexpression of protein kinases has also been shown to pro-
mote oncogenesis [50]. Thus we examined which protein kinases are overexpressed in PDAC
by analyzing gene expression profiles of previously published cDNA microarrays of primary
PDAC tumors (n = 30) and normal pancreas (n = 20) [38]. We identified differentially
expressed kinases using the Statistical Analysis of Microarrays (SAM) software [39,51]. Of
3899 differentially expressed genes between primary patient tumors and normal pancreas, 106
probes representing 91 kinases were identified (S1 Table).
We identified biological networks regulated by the differentially expressed kinases using
IPA. We found that the cell cycle was one of the most enriched biological pathways regulated
by our list of kinases in PDAC (Table 1, Figs 1A and 2), with 7 of the 10 most up-regulated
kinases (Table 2). Interestingly, three of these seven kinases are involved with the spindle
assembly checkpoint (SAC): BUB1, BUB1B, and TTK. Further interrogation of the gene
expression profiles found statistically significant co-overexpression of both kinase and non-
kinase components of the SAC in PDAC tumors compared to normal pancreas (Fig 1B).
Together these data suggest that the SAC may be important for mitotic fidelity in PDAC.
TTK kinase activity is essential to activate the SAC and prevent early anaphase onset [52–
55]. In order to evaluate the role of TTK we evaluated the expression of TTK at the protein
level and confirmed that a subset (43%) of primary PDAC patient samples had elevated TTK
protein expression compared to normal pancreas tissue (Fig 1C). In addition, we evaluated
TTK protein expression in a panel of 14 PDAC cell lines by immunoblot analysis (Fig 1D).
Five cell lines were selected with variable TTK expression for further investigation: HPAC,
SW-1990, AsPC-1, Panc 10.05 and PANC-1.
TTK is necessary for PDAC growth
To determine the functional consequence of TTK expression on PDAC growth we depleted
TTK in PDAC cell lines using a pool of 5 individually targeted siRNAs (S1 Fig). TTK protein
knockdown was confirmed by immunoblot analysis in four PDAC cell lines: AsPC-1, HPAC,
PANC-1, and Panc 10.05 (Fig 3A, S2 Fig panel A). Depletion of TTK in all four cell lines
decreased growth on plastic as determined by the thiazolyl blue tetrazolium bromide (MTT)
assay (Fig 3B, S2 Fig panel B). Catalytic inhibition of TTK with the AZ3146 TTK-selective
Table 1. Biological pathways with enrichment of differentially expressed kinases.
Network name p-value # of nodes
Post-translational modification 1.14E-67–3.85E-04 66
Cell cycle 6.76E-24–4.16E-04 43
Amino acid metabolism 1.46E-19–1.45E-08 18
Small molecule biochemistry 1.46E-19–2.42E-06 25
Cell death and survival 5.53E-19–4.16E-01 58
https://doi.org/10.1371/journal.pone.0174863.t001
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protein kinase inhibitor (AstraZeneca) phenocopied the decrease in proliferation seen with
siRNA silencing of TTK expression in HPAC and PANC-1 cells with a less dramatic effect in
Panc 10.05 cells. However, catalytic inhibition of TTK had no effect on AsPC-1 proliferation
despite equivalent drug administration (Fig 3C, S2 Fig Panel C).
We next examined the requirement for TTK to support PDAC transformed growth by mea-
suring anchorage-independent colony formation in soft agar, a standard assay for cellular
transformation. PANC-1 and HPAC cells with either genetic depletion or catalytic inhibition
of TTK showed significantly decreased anchorage-independent growth (Fig 3A, 3D–3F). In
addition, shRNA-mediated sustained knockdown of TTK demonstrated similar trends in the
inhibition of proliferation and transformed growth of PDAC cell lines. However, the magni-
tude of the inhibition was less pronounced than those observed following siRNA-mediated
knockdown of TTK, possibly due to incomplete knockdown of TTK or isolation of stably
infected cells that survived selection by compensating for the loss of TTK at the molecular level
(S3 Fig).
Fig 1. Increased expression spindle assembly checkpoint components and its regulator TTK in PDAC. (A) IPA software identified
prominent cellular functions that were significantly affected by differentially expressed kinases between normal and primary PDAC. (B)
Box and whisker plot of median, upper, and lower quartiles of mRNA expression of core components and regulators of the spindle assembly
checkpoint. Asterisk represent the p-value of the Mann-Whitney test (ns: p0.05, **: p0.01, ***: p0.001, ****: p0.0001). (C)
Expression of TTK in a panel of patient samples. N = normal pancreas and T = primary tumor. (D) Expression of TTK in immortalized
pancreas epithelium (HPNE and HPDE) and PDAC cell lines.
https://doi.org/10.1371/journal.pone.0174863.g001
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Override of the spindle assembly checkpoint and aberrant cell cycle
progression and mitotic aberrancies and apoptosis
It is well established that TTK is required for proper SAC activation and function [19]. To
understand the molecular mechanism whereby TTK supports PDAC growth we investigated
the effects of TTK inhibition on SAC activation. HPAC and PANC-1 cells were arrested in
mitosis with 100 ng/ml nocodazole and then challenged with 2 μM AZ3146. We monitored
the stability of the mitotic marker cyclin B to assess silencing of the SAC. Catalytic inhibition
of TTK caused a drop in the levels of cyclin B (Fig 4A), indicating that the catalytic inhibition
of TTK caused an escape from checkpoint mediated mitotic arrest and accelerated mitotic
Fig 2. Ingenuity pathway analysis of differentially expressed kinases in primary PDAC compared to normal
pancreas identified by unbiased methods. All 106 differentially regulated kinases were analyzed by integrated pathway
analysis using IPA. The posttranslational modification cell cycle, cellular assembly and organization, one of the most
dominant networks, is depicted here. Signaling pathways are colored according to expression, green representing down-
regulation and red representing up-regulation with the expression fold change represented by more intense colors.
https://doi.org/10.1371/journal.pone.0174863.g002
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progression. We next investigated the effect of checkpoint silencing on cell cycle progression.
We determined the cell cycle phase distribution of HPAC and PANC-1 cells treated with
siRNA or AZ3146 after 72 h by propidium iodide staining and flow cytometry analysis. Aber-
rant distribution of cells in each cell cycle phase occurred, specifically an increase post G2 cells,
indicative of multi-nucleation (Fig 4B and 4C).
TTK is required to prevent aneuploidy and apoptosis
Studies in other tumors have found that TTK depletion causes premature mitotic progression
and often results in aberrant chromosomal segregation and aneuploidy [30,56–58]. In PDAC,
TTK inhibition induced gains in the X chromosome and chromosome 17. However, the effect
of TTK inhibition on the nuclear architecture is unknown. We examined the nuclear architec-
ture of PANC-1 cells stably transduced with a lenti-viral vector encoding H2B-GFP followed
by depletion of TTK using siRNA. Fluorescent microscopy revealed gross multi- and micro-
nucleation in TTK depleted cell lines compared to mismatch siRNA controls, which reflected
widespread chromosomal segregation defects (Fig 4D and 4E). These results demonstrate the
requirement of TTK for mitotic fidelity and that depletion of TTK results in an increase of
chromosomal instability and aneuploidy.
Unstable aneuploidy is often associated with cell death from mitotic catastrophe. To assess
whether TTK silencing was associated with induction of apoptosis in PDAC cell lines, we
monitored apoptotic induction by measuring both positive annexin-V staining and caspase-3/
7 activity by flow cytometry and the Caspase-Glo 3/7 assay. siRNA mediated depletion of TTK
induced apoptosis in PANC-1, Panc 10.05 and SW-1990 cells but not AsPC-1 cells. Addition-
ally, only SW-1990 and Panc 10.05 cell lines exhibited a strong induction of apoptosis after cat-
alytic inhibition of TTK (Fig 4F–4H, S4 Fig). These results clearly demonstrate that apoptotic
induction can occur in PDAC following TTK depletion or catalytic inhibition but may be cell
line dependent.
Usp16 is a substrate of TTK
To further delineate the molecular mechanism whereby TTK regulates proper mitotic progres-
sion necessary for growth we sought to identify phosphorylation substrates of TTK. To identify
putative substrates of TTK we used the Scansite3 (http://scansite.mit.edu/) prediction software
and an input phosphorylation consensus motif recently identified by Hennrich et al. [59]. This
motif consists of a threonine residue with acidic amino acids in the −2, and/or −3 positions
and hydrophobic branched-chain amino acids (leucine, valine and isoleucine) in the +2 and
Table 2. Function of the 10 most overexpressed kinases.
Kinase Fold Change FDR (q-value) Function
BUB1 3.887 0 Cell cycle
NEK2 3.424 0 Cell cycle
CHEK1 3.362 0 Cell cycle
PTK6 3.213 0 Differentiation and apoptosis
TTK 2.972 0 Cell cycle
PBK 2.756 0 Cell cycle
STYK1 2.65 0.125 Proliferation and survival
MET 2.381 0 Growth factor sensing
CDK1 2.343 0 Cell cycle
BUB1B 2.114 0 Cell cycle
https://doi.org/10.1371/journal.pone.0174863.t002
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Fig 3. Genetic and pharmacologic inhibition of TTK decrease growth of PDAC cell lines. (A) Immunoblot analysis of HPAC
and PANC-1 cell extracts showing protein level of TTK in control mismatch siRNA (siMM) and a TTK siRNA (siTTK) pool 48 h after
transfection. (B) Growth of HPAC and PANC-1 PDAC cell lines transfected with control siMM and siTTK show reduced viability with
TTK depletion. Cells were measured for proliferation at 48, 72, and 120 h as indicated. (C) Growth of HPAC and PANC-1 PDAC cell
lines treated with DMSO control or 2 μM AZ3146. Cells were measured for proliferation at 48, 72, and 120 h as indicated. (D)
Representative images of colony formation of the PANC-1 cell line in soft agar. (E) Quantitation of colony formation in soft agar of
the HPAC and PANC-1 cell lines after transfection of either control or TTK targeted siRNA. Samples normalized to control. (F)
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+3 position [59]. Using this approach we identified 410 putative TTK phosphorylation sub-
strates in humans. Eight of these phosphorylation substrates have known roles in cell cycle reg-
ulation (Table 3). Addition of an aspartic acid or asparagine at the -1 position of the consensus
phosphorylation motif identified a single putative TTK phosphorylation substrate: ubiquitin
specific peptidase 16 (Usp16, also known as Ubp-M).
To examine if Usp16 is a direct phosphorylation substrate of TTK we performed an in vitro
kinase assay with [32P]ATP and measured substrate incorporation of 32P. Incorporation of 32P
on purified Usp16 was enhanced when incubated with active TTK (SignalChem) and inhibited
upon addition of 2 μM AZ3146 (Fig 5A). These results indicate that Usp16 is directly phos-
phorylated by TTK in vitro. We next sought to identify the TTK dependent phosphorylation
sites on Usp16 by performing mass spectrometry. TTK activity was stimulated with nocoda-
zole in 293FT cells exogenously expressing a flag-tagged Usp16. Cells were then concurrently
challenged with DMSO control or 2 μM AZ3146 for 4 h. FLAG-Usp16 from the cell lysate was
purified by immunoprecipitation, digested with trypsin, and enriched for phosphopeptides.
Amino acid composition of phosphopeptides was then identified by orbi-trap mass spectrome-
try. Analysis of the resulting spectra identified three TTK-dependent phosphorylation sites
within Usp16: S415, S552, T554 (Fig 5B).
TTK dependent phosphorylation of Usp16 causes protein degradation
To investigate the importance of phosphorylation of these three residues on Usp16 function
we created a GFP tagged phospho-mimetic mutant of Usp16 where glutamic acid residues
were substituted for the three identified phosphorylation sites (GFP-Usp16 3xE), and a phos-
pho-deficient mutant of Usp16 where alanine residues were substituted for the three identified
phosphorylation sites (GFP-Usp16-3xA). Immunoblot analysis of 293FT cells transfected with
cDNA expression vectors encoding wild type or mutant Usp16 revealed decreased expression
of the phospho-mimetic mutant of Usp16. RT-PCR with Usp16 specific primers confirmed
equivalent mRNA expression, suggesting that Usp16 phosphorylation promotes protein degra-
dation. Inhibition of the proteasome with 10 μM MG-132 restored expression of the phospho-
mimetic Usp16 mutant (Fig 5C–5E). Taken together, these data suggest that Usp16 is a
phosphorylation substrate of TTK and that Usp16 phosphorylation on S415, S552, or T554
leads to proteasome degradation of Usp16.
Discussion
An increased understanding of the biology of PDAC is essential to the identification of drug
targets for the development of better therapies. Chromosomal instability and aneuploidy are
characteristics of PDAC [8,60–64]. The SAC limits chromosomal instability by ensuring faith-
ful segregation of sister chromatids during mitosis. Here we show RNA overexpression of the
core components of the SAC in primary PDAC tumors compared to normal pancreas. We
hypothesize that targeting the SAC function may alter the ability of cancer cells to adapt to
aneuploidy and may be a possible therapy for PDAC.
TTK is a protein kinase required for SAC activation and was found to be overexpressed in
primary PDAC [19]. TTKwas a gene previously identified in a 25-gene signature associated
with chromosomal instability and aneuploidy in cancer [56]. Thus, overexpression of TTK
may represent an adaptive mechanism to sustain the growth of chromosomally unstable
Quantitation of colony formation in soft agar of the HPAC and PANC-1 cell lines after with continuous treatment with vehicle
(DMSO) or AZ3146. Normalized to DMSO control. Asterisk represent the P-value of the two-sided T-test (*:0.05, P **: P0.01).
Results representative of at least 2 independent experiments.
https://doi.org/10.1371/journal.pone.0174863.g003
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Fig 4. TTK inhibition overrides the SAC mediated cell cycle arrest and leads to aberrant cell cycle progression, multi-nucleation and apoptosis.
(A) Immunoblot of HPAC and PANC-1 PDAC cell lines arrested in mitosis by treatment with nocodazole. Cells were then treated with 2 μM AZ3146 for 4 h and
probed for expression of cyclin B1. (B) Representative flow cytometry plots of the cell cycle of HPAC and PANC-1 cell lines of 2 experiments. Cells were
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tumors. In support of this hypothesis, overexpression of TTK has been previously observed in
multiple tumor types including PDAC [32,33], breast [24–26,65], bladder [20], esophagus
[23], lung [22], anaplastic thyroid [21], and glioblastoma [30].
To investigate the role of TTK as an adaptive response to prevent excessive aneuploidy in
PDAC we investigated the effect of both catalytic and genetic depletion of TTK on mitotic
progression. Previous studies showed that pharmacologic inhibition of TTK catalytic activity
caused an aberrant override of the SAC mediated cell cycle arrest in PDAC [32,33]. We
found that this may be cell line dependent as knockdown and catalytic inhibition of TTK
increased aneuploidy in the PANC-1 but not the HPAC cell line. Although this result was
unexpected, previous reports have demonstrated heterogeneous response to TTK inhibition
[29]. The difference in response could perhaps be explained by the hypothesis that cells with
extra chromosomes may have a greater requirement for SAC function [16,32,66,67]. How-
ever, previous reported karyotypes show a modal number of 63 and 61 for the PANC-1 and
HPAC cell lines respectively, suggesting that the level of aneuploidy does not account for this
discrepancy [68,69]. Alternatively, the different TTK dependencies could be attributed to dif-
ferences in the genetic background of the two cell lines. Previous studies have shown that
aneuploidy can stimulate a p53-dependent senescence-like growth arrest [17,70,71]. PANC-
1 cells have inactivating mutations in both alleles of TP53, whereas HPAC cells have two
wild-type TP53 alleles [72]. Mitotic errors resulting from TTK inhibition in HPAC cells may
trigger p53 mediated growth arrest and prevent aneuploidy whereas PANC-1 lacking func-
tional p53 continue to aberrantly divide. Further investigation in more PDAC cell lines with
a wild-type TP53 background will be required to determine whether TTK inhibition induces
senescence-like phenotypes.
transfected with control or TTK targeted siRNA. 72 h post transfection cells were fixed and stained with propidium iodide. DNA content was assessed by flow
cytometry. (C) Quantitation of B showing distribution of cells in each phase of the cell cycle. (D) Confocal microscopy of the PANC-1 cell line stably expressing
a GFP-Histone 2B construct to visualize DNA. Chromosomal instability is visible in cells depleted of TTK in the form of multi- and micro-nucleation. (E)
Quantitation of cells with multi- or micro-nucleated phenotypes. (F) Scatterplots showing induction of apoptosis with depletion of TTK. PANC-1 cells were
transfected with control or a TTK targeted siRNA pool. 72 h post transfection cells were harvested and stained with the apoptotic marker Annexin V and the
counterstained with propidium iodide to visualize necrotic cells. (G) quantitation of the apoptotic induction of cells used in F.
https://doi.org/10.1371/journal.pone.0174863.g004
Table 3. Predicted TTK phosphorylation substrate with known mitotic roles.
Gene
Symbol
Gene Name Function
SKA3 Spindle and kinetochore-associated protein 3 Microtubule-binding subcomplex of the outer kinetochore that is essential for proper
chromosome segregation.
PDS5B Sister chromatid cohesion protein PDS5 homolog
B
Stabilizes cohesin complex association with chromatin.
USP16 Ubiquitin carboxyl-terminal hydrolase 16 Deubiquitinates H2A, one of two major ubiquitinated proteins of chromatin.
PSRC1 Proline/serine-rich coiled-coil protein 1 Required for normal congress of chromosomes at the metaphase plate, and for normal
rate of chromosomal segregation during anaphase.
APC1 Anaphase-promoting complex subunit 1 Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-
regulated E3 ubiquitin ligase that controls progression through mitosis and the G1
phase of the cell cycle.
PPP2R2D Serine/threonine-protein phosphatase 2A 55 kDa
regulatory subunit B delta isoform
Regulatory subunit of PP2A holoenzyme.
KNTC1 Kinetochore-associated protein 1 Essential component of the mitotic checkpoint that prevents cells premature mitotic exit.
Required for assembly of the dynein-dynactin and MAD1-MAD2 complexes onto
kinetochores.
WAPL Wings apart-like protein homolog Regulator of sister chromatid cohesion in mitosis, which negatively regulates cohesin
association with chromatin.
https://doi.org/10.1371/journal.pone.0174863.t003
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Fig 5. Usp16 is a TTK phosphorylation substrate. (A) In vitro kinase assay measuring TTK dependent phosphorylation by 32P incorporation
measured by liquid scintillation counts. Representative of 2 independent experiments. (B) Exogenously expressed FLAG-Usp16 was
immunoprecipitated from DMSO and AZ3146 treated mitotic 293FT cells, digested with trypsin and enriched for phosphopeptides.
Phosphorylated residues of Usp16 were identified by mass spectrometry. Spectral counts of representative individual experiments are shown.
(C) Immunoblot analysis of 293FT cells transiently transfected with control GFP, GFP-Usp16, GFP-Usp16 3xA (phosphodeficient mutant) or
GFP-Usp16 3xE (phosphomimetic mutant) and treated with control DMSO or MG-132. (D) Densitometry of (C). (E) RT-PCR of Usp16 using 2
independent Taqman probes from cells used in (C), normalized to β-actin and represented as percent of WT-Usp16.
https://doi.org/10.1371/journal.pone.0174863.g005
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Importantly, we found that knockdown of TTK significantly decreased PDAC cell line pro-
liferation and transformed growth in all four PDAC cell lines evaluated and that pharmaco-
logic inhibition decreased growth in three of four cell lines. Our results are in agreement with
prior reports in other tumor types where either pharmacologic inhibition or genetic knock-
down of TTK resulted in a similar decrease in the growth of multiple cancer cell lines [24,26–
30,32,73–75]. In addition, we observed that both transient and stable genetic depletion of TTK
decreased proliferation and transformed growth, demonstrating the immediate and prolonged
requirement of TTK in PDAC. One key observation from our study is the discordant response
seen in the AsPC-1 cell line. Whereas genetic depletion of TTK significantly decreased growth
on plastic, catalytic inhibition of TTK had no effect, suggesting that non-kinase domains of
TTK may be important to support continued proliferation of these aneuploid cells. Although
poorly characterized, the large non-catalytic N-terminus of TTK contains tandem tetratrico-
peptide repeats known to be important for protein binding [76–78]. Future studies will be
required to identify binding partners and characterize how they may contribute to adapting to
aneuploidy.
Apoptotic induction was observed in two of four cells lines in response to AZ3146 mediated
catalytic inhibition and genetic depletion. Interestingly, we observed that 72 h catalytic inhibi-
tion of TTK with AZ3146 did not induce apoptosis in the PANC-1 cell line whereas genetic
knockdown of TTK did. In contrast to our results, Slee et al. found that pharmacologic inhibi-
tion of TTK with NMS-P715 in PANC-1 cells did induce apoptosis [32]. Although PANC-1
cell lines show decrease growth in response to genetic depletion and catalytic inhibition, differ-
ences in apoptotic induction may be due to off target effects suggesting the need to further
characterize these pharmacologic inhibitors of TTK. Although the AsPC-1 cell line showed
decreased proliferation in response to genetic ablation, we unexpectedly observed that neither
genetic depletion nor catalytic inhibition of TTK induced apoptosis in the AsPC-1 cell line.
Cell death resulting from mitotic catastrophe has been previously reported without increased
apoptotic induction [79]. We hypothesize that cell line specific genetic lesions may determine
which cell death pathway is utilized and propose testing additional cells lines to identify bio-
markers that may predict response and further characterize these pathways.
In an attempt to characterize the molecular pathways downstream of TTK, we identified
Usp16 as a novel phosphorylation substrate of TTK. Usp16 dependent deubiquitination of his-
tone H2A is a prerequisite for chromosomal condensation [17,80,81]. We identified three
TTK-dependent phosphorylation sites on Usp16: S415, S552, and T554. Recently, CDK1
dependent phosphorylation of Usp16 on S552 was shown to promote an interaction between
Usp16 and Plk1. This interaction results in deubiquitination of Plk1 and sustained kinetochore
localization of Plk1 during metaphase that is necessary for initial kinetochore-microtubule
attachment, proper chromosome alignment, and timely chromatid segregation [82]. In addi-
tion, TTK has been found to cooperate with Plk1 to regulate the SAC through phosphorylation
of KNL-1 [83]. We show that point mutations in Usp16 (S415E, S552E, T554E) exhibited
enhanced degradation compared to wild-type Usp16. We propose that this triple phosphoryla-
tion and subsequent degradation of Usp16 may represent another mechanism whereby TTK
regulates genome stability by preventing Plk1 deubiquitination leading to its expulsion from
the kinetochore, as well as preventing chromosomal condensation by inhibiting histone H2A
deubiquitination, thus allowing more time to correct for errors that accumulated during DNA
replication. Future studies will be required to confirm whether TTK-dependent phosphoryla-
tion of Usp16 S552 plays a similar role in regulating Plk1 to maintain proper SAC function.
The high levels of chromosomal instability that exists in PDAC present a window that may
be exploited for therapy. Our results demonstrate that SAC inactivation through inhibition of
the upstream activator TTK decreases the ability of PDAC to adapt and support the growth of
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aneuploid cells. TTK inhibition has previously been shown to enhance the radiosensitivity of
human glioblastoma cells [31] as well as enhance chromosomal instability and sensitivity of
cancer cell lines when combined with the microtubule targeting drugs vincristine or paclitaxel
[14,29,30,84]. Consistent with this idea, the microtubule targeting nab-paclitaxel in combina-
tion with gemcitabine was approved for PDAC therapy [32,85]. Future studies will be required
to determine whether TTK inhibition sensitizes PDAC cells to nab-paclitaxel. Our results sup-
port the continued need to study molecular mechanisms that allow PDAC to adapt to chromo-
somal instability.
Supporting information
S1 Table. Overexpressed protein kinases in primary PDAC compared to normal pancreas,
with their respective fold change values and false discovery rates.
(PDF)
S1 Fig. Individual targeting of TTK of each siRNA used in the pool. Immunoblot analysis of
HPAC and PANC-1 cell lines 48 h after transfection with 10 nM siRNA targeting TTK.
(TIF)
S2 Fig. Transient TTK knockdown decreases growth in additional PDAC cell lines. (A)
Immunoblot of Panc 10.05 and AsPC-1 cell lines showing protein levels of TTK in control
mismatch siRNA (siMM) and a TTK siRNA (siTTK) pool 48 h after transfection. (B) Growth
of Panc 10.05 and AsPC-1 PDAC cell lines transfected with control siMM and siTTK show
reduced viability with TTK depletion. Cells were measured for proliferation at 48, 72, and 120
h as indicated. (C) Growth of Panc 10.05 and AsPC-1 PDAC cell lines treated with DMSO
control or 2 μM AZ3146. Cells were measured for proliferation at 48, 72, and 120 h as indi-
cated. Asterisk represent the P-value of the two-sided paired T-test (ns: P0.05, :0.05, P
: P0.01, : P0.001). Results representative of at least 2 experiments.
(TIF)
S3 Fig. Stable TTK knockdown decreases growth of PDAC cell lines. (A) Immunoblot of
HPAC and PANC-1 cell lines showing protein levels of TTK in control mismatch shRNA
(shNS) and TTK shRNA (shTTK3 and shTTK4) following infection and selection. (B) Growth
of PANC-1 and HPAC cell lines infected with control shNS and two shTTK constructs show
reduced viability with TTK depletion. Cells were measured for proliferation at 48, 72, and 120
h as indicated. (C) Transformed growth of PANC-1 and HPAC cell lines infected with control
shNS and two shTTK constructs demonstrated reduced growth. Asterisk represent the P-value
of the two-sided paired T-test (:0.05, P : P0.01). Results representative of at least 2 exper-
iments.
(TIF)
S4 Fig. Caspase 3/ 7activity in PDAC cell lines with TTK inhibition. (A) Immunoblot of
Panc 10.05 and AsPC-1 cell lines showing protein levels of TTK in control mismatch siRNA
(siMM) and a TTK siRNA (siTTK) pool 48 h after transfection. (B) Enzymatic activities of cas-
pase 3/7 were measured in AsPC-1, SW-1990, PANC-1 and Panc 10.05 cell lines 72 hours after
transfection with TTK targeting siRNA. Relative luminescence is expressed in the bar graph.
(C) Enzymatic activities of caspase 3/7 were measured in AsPC-1, SW-1990, PANC-1 and Panc
10.05 cell lines 72 hours after administration of DMSO control or 2 μM AZ3146. Relative lumi-
nescence is expressed in the bar graph. Asterisk represent the P-value of the two-sided T-test
paired (:0.05, P : P0.01, : P0.001). Results representative of at least 2 experiments.
(TIF)
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